跳至主要内容
临床试验/NCT00002511
NCT00002511已完成3 期

PHASE III STUDY OF POST-OPERATIVE EXTERNAL RADIOTHERAPY IN PATHOLOGICAL STAGE T3 N0 PROSTATIC CARCINOMA

European Organisation for Research and Treatment of Cancer - EORTC1 个研究点 分布在 1 个国家目标入组 1,005 人开始时间: 1992年12月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
1,005
试验地点
1

研究概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.

PURPOSE: Randomized phase III trial to compare radiation therapy with no further treatment in treating patients with stage III prostate cancer following radical prostatectomy.

详细描述

OBJECTIVES:

  • Compare local recurrence rates, acute and late morbidity, overall survival, disease-free survival, and cancer-related survival of patients with pT3 pN0 adenocarcinoma of the prostate randomized following radical prostatectomy to postoperative conventional pelvic irradiation (60 Gy) vs no further treatment until relapse.
  • Better define the selective pathologic indications for radiotherapy in patients with pT3 pN0 disease.

OUTLINE: This is a randomized study.

  • Arm I: Patients undergo radiotherapy daily, 5 days a week, for 5 weeks, followed by boost radiotherapy for 1-1.4 weeks.
  • Arm II: Patients are observed. Local relapse is treated with conventional pelvic radiotherapy.

Patients are followed every 3 months during the first postoperative year, every 6 months until the fifth year, and annually thereafter.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
— 至 75 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •DISEASE CHARACTERISTICS:
  • •Histologically documented invasive adenocarcinoma of the prostate staged pT3 pN0 after radical prostatectomy
  • •Preoperative staging must have been T0-3 N0 M0 based on physical exam, chest x-ray, bone scan, CT or MRI of entire pelvis and abdomen, and serum PSA
  • •At least 1 of the following features must be present:
  • •Complete capsule invasion (i.e., perforation)
  • •Positive surgical margins (microscopic or gross)
  • •Seminal vesicle invasion
  • •Radiotherapy must begin within 16 weeks following surgery, after recovery of urinary function
  • •PATIENT CHARACTERISTICS:
  • •75 and under
  • •Performance status:
  • •Hematopoietic:
  • •Not specified
  • •Not specified
  • •Not specified
  • •No other malignancies
  • •PRIOR CONCURRENT THERAPY:
  • •Biologic therapy:
  • •Not specified
  • •Chemotherapy:
  • •Not specified
  • •Endocrine therapy:
  • •No more than 4 months of preoperative hormonal therapy
  • •Radiotherapy:
  • •Not specified
  • •Radical prostatectomy required within 12 weeks with recovery of urinary function

排除标准

  • 未提供

研究者

申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验